HAYA Therapeutics Appoints Jordan Shin, M.D., Ph.D. as Chief Medical Officer
Slice of Healthcare Team
Sep 13, 2024
Key Highlights
- HAYA Therapeutics appoints Dr. Jordan Shin as Chief Medical Officer.
- Dr. Shin brings over a decade of experience in cardiovascular and lung translational medicine.
- He will lead the clinical development of HTX-001 for non-obstructive hypertrophic cardiomyopathy.
- Prior leadership roles at LEXEO Therapeutics and Renovacor, and academic tenure at Harvard Medical School.
Source: Business Wire
Notable Quotes
“ Dr. Shin’s strong background in translational research and clinical development will help us bring this and other important medicines to those in need. ”
Samir Ounzain, Ph.D., Co-founder and CEO at HAYA Therapeutics
“ HAYA's full-stack RNA-guided regulatory genome platform uniquely positions the company to make a significant impact on patients suffering from cardiovascular diseases. ”
Jordan Shin, M.D., Ph.D., Chief Medical Officer at HAYA Therapeutics
-2e14ed90-63f5-4ce1-84fc-3fa9506b84be.png&w=3840&q=75)
